2min chapter

Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

CHAPTER

Valgan Cycle of Your Isn't a Med That's Necessarily Easy to Access.

The efficacy held for all subgroups, including those receiving lymphocyte depleting induction. There were significantly more adverse events for patients treated with valgan cycle of your 37% developed leukemia versus 11.3% in the La Terma Vier arm. The neutropenia was 16.5% versus 2.7%. And two times as many patients ended up needing GCSF to treat this adverse event. I just, to me, these are absolutely practice changing data.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode